| First Author | Karni-Schmidt O | Year | 2011 |
| Journal | Am J Pathol | Volume | 178 |
| Issue | 3 | Pages | 1350-60 |
| PubMed ID | 21356385 | Mgi Jnum | J:169680 |
| Mgi Id | MGI:4941654 | Doi | 10.1016/j.ajpath.2010.11.061 |
| Citation | Karni-Schmidt O, et al. (2011) Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression. Am J Pathol 178(3):1350-60 |
| abstractText | The TP63 gene, a member of the TP53 tumor suppressor gene family, can be expressed as at least six isoforms due to alternative promoter use and alternative splicing. The lack of p63 isoform-specific antibodies has limited the analysis of the biological significance of p63. We report a novel set of well-defined antibodies to examine p63 isoforms in mouse and human urothelium during embryogenesis and tumor progression, respectively. We provide evidence that basal and intermediate urothelial cells express p63 isoforms, with the TAp63 variant the first to be detected during development, whereas umbrella cells are characterized by a p63-negative phenotype. Notably, we report that p63-null mice develop a bladder with an abnormal urothelium, constituted by a single layer of cells that express uroplakin II and low molecular weight cytokeratins, consistent with an umbrella cell phenotype. Finally, analysis of 202 human bladder carcinomas revealed a new categorization of invasive tumors into basal-like (positive for DeltaNp63 and high molecular weight cytokeratins and negative for low molecular weight cytokeratins) versus luminal-like (negative for DeltaNp63 and high molecular weight cytokeratins and positive for low molecular weight cytokeratins) phenotypes, with DeltaNp63 expression associated with an aggressive clinical course and poor prognosis. This study highlights the relevance of p63 isoforms in both urothelial development and bladder carcinoma progression, with DeltaNp63 acting as an oncogene in certain invasive bladder tumors. |
